Effective Analysis of Atorvastatin Versus in Simvastatin Patients with Hyperlipidemia (original) (raw)
A 6-month trial of simvastatin (HMG-CoA reductase inhibitor) in the treatment of hypercholesterolaemia
W. J. Hayward Vermaak
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1991
View PDFchevron_right
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease
Ingar Holme
The American journal of cardiology, 2002
View PDFchevron_right
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups
Ivan Escobar
Clinical Cardiology, 2003
View PDFchevron_right
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: The treat-to-target (3T) study
Mogens Larsen
Clinical Therapeutics, 2003
View PDFchevron_right
Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study
Yoshiharu Tsubakihara, Masayasu Matsumoto
Clinical Therapeutics, 1997
View PDFchevron_right
Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin
Loukianos Rallidis
View PDFchevron_right
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
Adrians Dobs, Evan Stein
Clinical Cardiology, 2003
View PDFchevron_right
A single-centre retrospective observational study to evaluate the change in total cholesterol and LDL cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin
Frederick Raal
PubMed, 2004
View PDFchevron_right
Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia
WILLIAM CROMWELL
The American Journal of Cardiology, 2001
View PDFchevron_right
Lipid modifying action of atorvastatin in escalating doses in patients of coronary artery disease
Sajjad Hossain
International Journal of Basic & Clinical Pharmacology, 2014
View PDFchevron_right
The Comparison of Simvastatin and Atorvastatin Efficacy in Lowering Lipid Profile and Apolipoprotein-B of Diabetic Dyslipidemia Patient
Sony Wibisono
2013
View PDFchevron_right
Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels
Gloria Vega
The American Journal of Cardiology, 2001
View PDFchevron_right
Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia
Ivan Tkáč, Martin Javorský
Pharmacological Research, 2006
View PDFchevron_right
Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia
Ole Faergeman
American Heart Journal, 2005
View PDFchevron_right
Lipid-Altering Efficacy and Safety of Simvastatin 80 mg/Day: Long-Term Experience in a Large Group of Patients with Hypercholesterolemia
Ivan Escobar
Clinical Cardiology, 2000
View PDFchevron_right
Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients
Quansheng Zhu
Molecular and cellular biochemistry, 2000
View PDFchevron_right
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin
J. Ducobu, Yvon Carpentier
International Journal of Cardiology, 2005
View PDFchevron_right
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia
Danijela Ristic-Medic
The American Journal of Cardiology, 1990
View PDFchevron_right
Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia
Salvatore Turco
Diabetes, Obesity and Metabolism, 2000
View PDFchevron_right
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes
Sud Ramachandran
Annals of Clinical Biochemistry, 2010
View PDFchevron_right
Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial
Mark Kipnes
Clinical Therapeutics, 2004
View PDFchevron_right
Lipid-altering efficacy and safety of simvastatin in women and elderly patients with hypercholesterolemia
Evan Stein
Atherosclerosis, 2000
View PDFchevron_right
Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F2-Isoprostane Formation in Hypercholesterolemic Subjects: No Further Effect of Vitamin E
Raffaella Muraro
Circulation, 2002
View PDFchevron_right
The role of HMG-CoA reductase inhibitors in the treatment of hyperlipidemia: a review of fluvastatin
jean deslypere
Current Therapeutic Research, 1995
View PDFchevron_right
Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F 2 -Isoprostane Formation in Hypercholesterolemic Subjects
paola marchesani
Circulation, 2002
View PDFchevron_right
Effects of Low-Dose Atorvastatin and Rosuvastatin on Plasma Lipid Profiles
Claudia Stefanutti
American Journal of Cardiovascular Drugs, 2008
View PDFchevron_right
Rosuvastatin: A Highly Effective New HMG-CoA Reductase Inhibitor
Ali Raza
Cardiovascular Drug Reviews, 2006
View PDFchevron_right